ArticleCureus2026
Synchronous Bilateral Breast Invasive Ductal Carcinoma With Osteoclast-Like Stromal Giant Cells in a 44-Year-Old Woman: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast carcinoma with osteoclast-like stromal giant cells (OCGC) is a rare histological variant of invasive breast carcinoma. While it typically presents as a unilateral disease, its clinicopathological significance and the mechanisms underlying its formation remain incompletely understood. To our knowledge, a case of synchronous bilateral primary invasive ductal carcinoma with OCGCs has not been previously reported. A 44-year-old premenopausal woman was diagnosed with synchronous bilateral invasive ductal carcinoma with OCGCs. Imaging revealed small masses in both breasts, and core needle biopsies demonstrated invasive carcinoma with associated non-invasive components and numerous OCGCs in the tumor stroma. Both tumors were hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative (luminal A-like). The patient underwent bilateral mastectomy and sentinel lymph node biopsy, which showed no lymph node metastasis. The postoperative course was uneventful, and the patient has remained recurrence-free for six months after surgery. Notably, final pathological examination confirmed independent ductal carcinoma in situ (DCIS) components with OCGCs in both breasts, supporting the diagnosis of bilateral primary tumors rather than metastatic disease. Immunohistochemically, the OCGCs were CD68-positive, confirming their macrophage lineage. Genetic testing showed no pathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.